Home
SVRA
SVRA News

Latest Savara Inc. (SVRA) News on August 16, 2025

Savara Independent Director Acquires 177% More Stock

Simply Wall St.

2 months ago

Savara Independent Director Acquires 177% More Stock

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating

MT Newswires

3 months ago

HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6

MT Newswires

3 months ago

Top Midday Decliners

MT Newswires

3 months ago

Savara Receives FDA Refusal to File Letter for BLA of Potential Autoimmune PAP Therapy; Shares Fall Pre-Bell

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Business Wire

3 months ago

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Biogen strikes RNAi deal with City; Aurion withdraws IPO

BioPharma Dive

3 months ago

Biogen strikes RNAi deal with City; Aurion withdraws IPO

Savara Announces New Employment Inducement Grant

Business Wire

3 months ago

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Jefferies Global Healthcare Conference

Business Wire

3 months ago

Savara Announces Participation in Jefferies Global Healthcare Conference

Savara Inc. (SVRA): Analysts See 212% Upside Potential

Insider Monkey

3 months ago

Savara Inc. (SVRA): Analysts See 212% Upside Potential

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

Business Wire

3 months ago

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

Business Wire

3 months ago

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

Business Wire

3 months ago

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Business Wire

4 months ago

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Savara Announces New Employment Inducement Grant

Business Wire

4 months ago

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Business Wire

4 months ago

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 04/02/2025

MT Newswires

5 months ago

Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Business Wire

5 months ago

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

MT Newswires

5 months ago

Savara Gets Up to $200 Million Loan From Hercules Capital

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Business Wire

5 months ago

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

MT Newswires

5 months ago

Savara Files Biologics License Application to US FDA for Molbreevi to Treat Lung Disease

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

5 months ago

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Business Wire

5 months ago

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

MT Newswires

5 months ago

Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

5 months ago

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the Leerink Global Healthcare Conference

Business Wire

5 months ago

Savara Announces Participation in the Leerink Global Healthcare Conference

Savara Announces New Employment Inducement Grant

Business Wire

6 months ago

Savara Announces New Employment Inducement Grant

Positive Signs As Multiple Insiders Buy Savara Stock

Simply Wall St.

6 months ago

Positive Signs As Multiple Insiders Buy Savara Stock

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Business Wire

7 months ago

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Business Wire

7 months ago

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

Simply Wall St.

8 months ago

Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company

MT Newswires

8 months ago

Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target

MT Newswires

8 months ago

Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

8 months ago

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

8 months ago

Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Simply Wall St.

9 months ago

Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)

Savara Announces New Employment Inducement Grant

Business Wire

9 months ago

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Business Wire

9 months ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 11/21/2024

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 11/19/2024

MT Newswires

9 months ago

Savara Insider Bought Shares Worth $287,600, According to a Recent SEC Filing

Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

GuruFocus.com

9 months ago

Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate

Savara Announces Participation in Upcoming Healthcare Conferences

Business Wire

9 months ago

Savara Announces Participation in Upcoming Healthcare Conferences

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

9 months ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Business Wire

9 months ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV

Business Wire

10 months ago

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV

Savara Announces New Employment Inducement Grant

Business Wire

10 months ago

Savara Announces New Employment Inducement Grant

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Business Wire

a year ago

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

MT Newswires

a year ago

Savara Initiates Early Access Program for Rare Lung Disease Treatment

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

a year ago

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Business Wire

a year ago

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

Savara to Host Analyst and Investor Webinar on September 30, 2024

Business Wire

a year ago

Savara to Host Analyst and Investor Webinar on September 30, 2024

MT Newswires

a year ago

Savara's Lung Disease Therapy Improves Disease Severity Score in Phase 3 Study

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Business Wire

a year ago

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

Savara Announces New Employment Inducement Grant

Business Wire

a year ago

Savara Announces New Employment Inducement Grant

Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks

Simply Wall St.

a year ago

Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire

a year ago

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?

Insider Monkey

a year ago

Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?

Savara Announces New Employment Inducement Grant

Business Wire

a year ago

Savara Announces New Employment Inducement Grant

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Business Wire

a year ago

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week

Simply Wall St.

a year ago

Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week

Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?

Insider Monkey

a year ago

Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?

MT Newswires

a year ago

Savara Prices $100 Million Common Shares Offering

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

Business Wire

a year ago

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

MT Newswires

a year ago

JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating

MT Newswires

a year ago

Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating

MT Newswires

a year ago

Guggenheim Adjusts Price Target on Savara to $10 From $8, Maintains Buy Rating

MT Newswires

a year ago

HC Wainwright Raises Savara Price Target to $10 From $6, Maintains Buy Rating

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Savara's Phase 3 Trial for Molgramostim Nebulizer Solution Meets Primary Endpoint; Shares Rise Pre-Bell

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

a year ago

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Business Wire

a year ago

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

Simply Wall St.

a year ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

a year ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Simply Wall St.

a year ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled

Motley Fool

a year ago

3 Mistakes That Can Get Your Costco Membership Canceled

Savara to Present at the Jefferies Global Healthcare Conference

Business Wire

a year ago

Savara to Present at the Jefferies Global Healthcare Conference

MT Newswires

a year ago

Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Business Wire

a year ago

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara Announces New Employment Inducement Grant

Business Wire

a year ago

Savara Announces New Employment Inducement Grant

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

Savara to Present at the Citizens JMP Life Sciences Conference

Business Wire

a year ago

Savara to Present at the Citizens JMP Life Sciences Conference

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Business Wire

a year ago

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara Announces New Employment Inducement Grant

Business Wire

a year ago

Savara Announces New Employment Inducement Grant

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

Business Wire

a year ago

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

Business Wire

a year ago

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

Savara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?

Simply Wall St.

a year ago

Savara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?

Why Beazer Homes Stock Dropped Today

Motley Fool

2 years ago

Why Beazer Homes Stock Dropped Today

Digi International Inc. (NASDAQ:DGII) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

Digi International Inc. (NASDAQ:DGII) Q1 2024 Earnings Call Transcript

Savara Announces New Employment Inducement Grant

Business Wire

2 years ago

Savara Announces New Employment Inducement Grant

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Brandywine Realty Trust Earnings Call

Associated Press Finance

2 years ago

Benchmark: Q4 Earnings Snapshot

BENCHMARK REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS

PR Newswire

2 years ago

BENCHMARK REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS

Savara to Present at Two Upcoming Healthcare Conferences

Business Wire

2 years ago

Savara to Present at Two Upcoming Healthcare Conferences

Share on Social Networks: